UNRESECTABLE HEPATOCELLULAR CARCINOMA

This study observes how a combination of two immunotherapy drugs, nivolumab and ipilimumab, works for people with advanced liver cancer that cannot be removed by surgery. It follows adults receiving this treatment as part of their routine medical care in Japan to understand its s…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This study is testing a combination of three treatments—radioactive beads (SIRT-Y90), an immunotherapy drug (atezolizumab), and a drug that cuts off tumor blood supply (bevacizumab)—for people with advanced liver cancer that cannot be surgically removed. Researchers will track ho…

This study tests a new approach for people with advanced liver cancer that cannot be surgically removed. Participants receive radiation followed by an injection of their own specially trained immune cells (dendritic cells), a pneumonia vaccine to boost immunity, and immunotherapy…

This phase 3 trial is testing whether adding two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. The study will enroll 101 participants wi…

This study tests a combination of internal radiation (Y90-SIRT) with three drugs (nivolumab, ipilimumab, and lenvatinib) in 33 people with liver cancer that cannot be surgically removed. The goal is to see if this powerful mix is safe and can shrink tumors or extend survival. It …

This study tests the safety of combining two drugs (atezolizumab and bevacizumab) with targeted radiation (SBRT) in 20 adults with liver cancer that cannot be surgically removed. The goal is to see if this triple therapy is tolerable and can help control the disease. Participants…

This pilot study is testing whether combining stereotactic body radiation therapy (SBRT) with immunotherapy can shrink liver tumors that are too large or widespread to be surgically removed. The goal is to make these tumors operable, giving patients a chance at curative surgery. …

This phase II trial tests whether adding the immunotherapy drug atezolizumab to a targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. The study enrolls 122 adults whose…

This study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…